Science Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration, a Leading Cause of Blindness

Source Summary

ALAMEDA, Calif. & PARIS--(BUSINESS WIRE)--Science Corporation, the neural engineering and brain-computer interface (BCI) company, today announced the European commercial launch of PRIMA, the first and only treatment shown in clinical trials to restore functional central vision to patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD), a leading cause of blindness. PRIMA has received a CE (Conformité Européenne) mark under the European Union Medical Device Regulat